ADM (NYSE: ADM), a global leader in natural solutions, has announced the approval of its spore-forming probiotic DE111? (Bacillus subtilis) by the Therapeutic Goods Administration (TGA), an entity within the Australian Department of Health. This marks a significant expansion of DE111?'s availability, following its recent approval by the National Health Commission (NHC) in China.
Helen Hu, president of health & wellness APAC at ADM, stated, "This is an important milestone for ADM, as it marks the first Bacillus subtilis strain to be approved by the TGA in Australia. By expanding access to DE111?, we're facilitating new innovation possibilities for our Australian customers, enabling the development of pioneering gut health-supporting products. Additionally, the continued approval of DE111? by important government authorities demonstrates its high quality, safety and alignment with strict regulatory standards."
Clinically documented results demonstrate several health benefits of DE111?, including support for digestive health and healthy immune function. It is capable of surviving the stomach's harsh environment and germinating in the small intestine, thereby promoting a healthy gastrointestinal tract, gut function, and microbiome diversity.
"DE111? is a spore-forming probiotic, which means it can withstand harsh formulation environments that may otherwise damage conventional probiotics. This robustness is paving the way for new, convenient and enjoyable foods, beverages and dietary supplements that meet people where they are on their wellness journeys, especially as more consumers make the connection between their gut and digestive health and other aspects of well-being," continued Hu.
In Australia, a significant majority of consumers (81%) recognize a link between digestive health and overall well-being, with 76% seeing a specific connection to immune function. Additionally, 64% of Australian consumers have used probiotics or cultures to address digestive health concerns over the past year. The Australian probiotic supplement market is expected to grow, with Euromonitor predicting a CAGR of 2.7% from 2023 to 2028.
*DE111? is a trademark of Deerland Probiotics & Enzymes, Inc. in the US and other countries. Local regulations must be reviewed to confirm the permissibility of ingredients for each food category.
